Maxim Partners invests in KGK Science
Saturday, August 8, 2026 · first reported by Private Capital Journal
Maxim Partners led a growth investment in KGK Science, a North American contract research organization specializing in clinical trials; closed June 30, 2026, financial terms undisclosed.
- Firm
- Maxim Partners
- Also named
- KGK Science Inc.
- Asset class
- Private equity
- Geography
- North America
The summary and fields above are extracted from the published reports and can contain errors. The linked articles are the source of record.
See an error?
More in Deals
From the same day- Blackstone, KKR and Brookfield agree $16bn Kuwait pipeline investmentPrivate Equity Wire
- ECP, KKR agree to acquire DCC Energy in $7.7bn dealPE Hub
- Carlyle and Bain Capital in final race for $7bn Wealth Enhancement dealPrivate Equity Wire
- Arlington closes $1.45bn sale of Riverpoint Medical to NovantaPE Hub
- EQT raises Perpetual offer to AUD2.55bn in third takeover approachPrivate Equity Wire
- TransDigm to acquire IGP-backed Prince & Izant for over $1bnPE Hub
Got news? Send it to us →